- Home
- NXTC vs NCPL Comparison
NXTC vs NCPL Comparison
Compare NXTC & NCPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- NCPL
- Stock Information
- Founded
- NXTC 2015
- NCPL 1984
- Country
- NXTC United States
- NCPL United States
- Employees
- NXTC N/A
- NCPL N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- NCPL Investment Managers
- Sector
- NXTC Health Care
- NCPL Finance
- Exchange
- NXTC Nasdaq
- NCPL Nasdaq
- Market Cap
- NXTC 13.9M
- NCPL 11.7M
- IPO Year
- NXTC 2019
- NCPL N/A
- Fundamental
- Price
- NXTC $6.17
- NCPL $3.19
- Analyst Decision
- NXTC Strong Buy
- NCPL
- Analyst Count
- NXTC 3
- NCPL 0
- Target Price
- NXTC $33.00
- NCPL N/A
- AVG Volume (30 Days)
- NXTC 299.6K
- NCPL 906.1K
- Earning Date
- NXTC 08-04-2025
- NCPL 09-15-2025
- Dividend Yield
- NXTC N/A
- NCPL N/A
- EPS Growth
- NXTC N/A
- NCPL N/A
- EPS
- NXTC N/A
- NCPL N/A
- Revenue
- NXTC N/A
- NCPL $812,612.00
- Revenue This Year
- NXTC N/A
- NCPL N/A
- Revenue Next Year
- NXTC N/A
- NCPL $101.16
- P/E Ratio
- NXTC N/A
- NCPL N/A
- Revenue Growth
- NXTC N/A
- NCPL N/A
- 52 Week Low
- NXTC $2.69
- NCPL $1.41
- 52 Week High
- NXTC $20.76
- NCPL $8.75
- Technical
- Relative Strength Index (RSI)
- NXTC 62.21
- NCPL 40.41
- Support Level
- NXTC $4.75
- NCPL $2.92
- Resistance Level
- NXTC $5.23
- NCPL $3.43
- Average True Range (ATR)
- NXTC 0.56
- NCPL 0.84
- MACD
- NXTC 0.10
- NCPL -0.38
- Stochastic Oscillator
- NXTC 86.74
- NCPL 7.47
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.